7 results on '"OVERALL survival"'
Search Results
2. Survival Outcomes and PROs Favor Cemiplimab + Chemotherapy vs Chemotherapy Alone in Advanced NSCLC Regardless of PD-L1 Status.
3. Clinical Updates: PROSTATE CANCER. Darolutamide delays time to progression from mHSPC to mCRPC vs placebo.
4. Prostate cancer treatment deintensification: When less is more.
5. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.
6. Allogeneic Stem Cell Transplant Shows Minimal OS, PFS Benefits in Patients With MM.
7. Hypertension predicts worse outcomes for patients undergoing nephroureterectomy for UTUC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.